Table 1.
Baseline Characteristics of modified intent-to-treat analysis set (70% information fraction).
| Baseline characteristics | N-AVD n=487 N (%) |
Bv-AVD n=483 N (%) |
|---|---|---|
| Age, median (range) | 27.6 (12.0–83.7) | 26.8 (12.0–81.7) |
| 12–17 years | 118 (24%) | 118 (24%) |
| 18–60 years | 321 (66%) | 318 (66%) |
| > 60 years | 48 (10%) | 47 (10%) |
|
| ||
| Female Sex | 216 (44%) | 210 (43%) |
|
| ||
| Race | ||
| White | 372 (76%) | 361 (75%) |
| Black | 58 (12%) | 56 (11%) |
| Asian | 11 (2%) | 17 (4%) |
| Other/Unknown | 46 (9%) | 49 (10%) |
|
| ||
| Hispanic ethnicity | 66 (14%) | 58 (12%) |
|
| ||
| Stage | ||
| III | 185 (38%) | 168 (35%) |
| IV | 302 (62%) | 315 (65%) |
|
| ||
| B symptoms present | 288 (59%) | 273 (57%) |
|
| ||
| IPS Score | ||
| 0–3 | 332 (68%) | 328 (68%) |
| 4–7 | 155 (32%) | 155 (32%) |
|
| ||
| Bulky disease > 10cm | 156 (32%) | 127 (26%) |
|
| ||
| HIV positive | 11 (2%) | 5 (1%) |
N-AVD = nivolumab, doxorubicin, vinblastine, dacarbazine; BV-AVD = brentuximab vedotin, doxorubicin, vinblastine, dacarbazine; IPS = international prognostic score; HIV = human immunodeficiency virus